Apr 2024 $5 M Private placement after listing $2 to $10 million 1
Oncobiologics, Inc.: Private sale, Apr 2024 × Investors in this round 1 investor had bought by the notice of Apr 16, 2024: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $13 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice C. Russell Trenary · Executive Officer, Director Jeff Russell Evanson · Executive Officer Lawrence A. Kenyon · Executive Officer, Director Andong G. Huang · Director Faisal G. Sukhtian · Director Gerd G. Auffarth · Director Julia A. Haller · Director Julian G. Gangolli · Director Kurt J. Hilzinger · Director Randy H. Thurman · Director Yezan H. Haddadin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount above includes the amount, if any, that the Issuer could receive if all of the issued Warrants were exercised.”Signed by Lawrence Kenyon, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Apr 16, 2024. Read the notice at the SEC .
equity, options SEC Mar 2024 $60 M Private placement after listing $50 to $250 million 21
Oncobiologics, Inc.: Private sale, Mar 2024 × Investors in this round 21 investors had bought by the notice of Mar 29, 2024: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $60 M of $159 M offered; $99 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $3,600,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice C. Russell Trenary · Executive Officer, Director Jeff Russell Evanson · Executive Officer Lawrence A. Kenyon · Executive Officer, Director Andong G. Huang · Director Faisal G. Sukhtian · Director Gerd G. Auffarth · Director Julia A. Haller · Director Julian G. Gangolli · Director Kurt J. Hilzinger · Director Randy H. Thurman · Director Yezan H. Haddadin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount above includes the amount, if any, that the Issuer could receive if all of the issued Warrants were exercised.”Signed by Lawrence Kenyon, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Mar 29, 2024. Read the notice at the SEC .
equity, options SEC Dec 2022 $1 M Private placement after listing Under $2 million 1
Oncobiologics, Inc.: Private sale, Dec 2022 × Investors in this round 1 investor had bought by the notice of Jan 6, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice C. Russell Trenary · Executive Officer, Director Lawrence A. Kenyon · Executive Officer, Director Andong G. Huang · Director Faisal G. Sukhtian · Director Gerd G. Auffarth · Director Julia A. Haller · Director Julian G. Gangolli · Director Kurt J. Hilzinger · Director Randy H. Thurman · Director Yezan H. Haddadin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Consists of warrants to purchase 515,755 shares of common stock at an exercise price of $2.00 per share issued to M.S. Howells & Co. as placement agent compensation in connection with a registered direct equity offering that is not reported here.”Signed by Lawrence Kenyon, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Jan 6, 2023. Read the notice at the SEC .
options SEC Feb 2021 $4 M Private placement after listing $2 to $10 million 2
Oncobiologics, Inc.: Private sale, Feb 2021 × Investors in this round 2 investors had bought by the notice of Feb 12, 2021: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Lawrence A. Kenyon · Executive Officer, Director Andong G. Huang · Director Faisal G. Sukhtian · Director Gerd G. Auffarth · Director Julian G. Gangolli · Director Kurt J. Hilzinger · Director Randy Thurman · Director Yezan Haddadin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lawrence Kenyon, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 12, 2021. Read the notice at the SEC .
equity SEC Jun 2020 $16 M Private placement after listing $10 to $50 million 1
Oncobiologics, Inc.: Private sale, Jun 2020 × Investors in this round 1 investor had bought by the notice of Jun 9, 2020: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $16 M of $16 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeff G. Evanson · Executive Officer Lawrence A. Kenyon · Executive Officer, Director Terry G. Dagnon · Executive Officer Faisal G. Sukhtian · Director Gerd G. Auffarth · Director Julian G. Gangolli · Director Kurt J. Hilzinger · Director Randy Thurman · Director Yezan Haddadin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lawrence Kenyon, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 9, 2020. Read the notice at the SEC .
equity SEC Feb 2020 $8 M Private placement after listing $2 to $10 million 7
Oncobiologics, Inc.: Private sale, Feb 2020 × Investors in this round 7 investors had bought by the notice of Mar 11, 2020: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $540,400
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeff G. Evanson · Executive Officer Lawrence A. Kenyon · Executive Officer, Director Terry G. Dagnon · Executive Officer Faisal G. Sukhtian · Director Kurt J. Hilzinger · Director Randy Thurman · Director Yezan Haddadin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · Newyork, New York Sold in IL, NJ, NY Remarks in the notice On fees: “In addition, the placement agent was reimbursed $135,000 for expenses relating to the offering and received $77,200 for management fees.”On the amounts: “Includes amounts receivable upon the exercise of warrants; such warrants have not yet been exercised”Signed by Lawrence Kenyon, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 11, 2020. Read the notice at the SEC .
equity, options SEC Sep 2017 $3 M Private placement after listing $2 to $10 million 1
Oncobiologics, Inc.: Private sale, Sep 2017 × Investors in this round 1 investor had bought by the notice of Sep 25, 2017: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $40 M offered; $37 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Preferred Stock convertible into Common Stock and Warrants to purchase Common Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elizabeth A. Yamashita · Executive Officer Kenneth M. Bahrt · Executive Officer Lawrence C. Kenyon · Executive Officer Pankaj Mohan · Executive Officer, Director Scott A. Gangloff · Executive Officer Stephen J. McAndrew · Executive Officer Albert D. Dyrness · Director Faisal G. Sukhtian · Director Joe C. Thomas · Director Kurt J. Hilzinger · Director Scott G. Canute · Director Todd C. Brady · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes proceeds of up to $15,075,000 upon future exercise of the Warrants.”Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 25, 2017. Read the notice at the SEC .
equity, options SEC Dec 2015 $6 M No. 3 $2 to $10 million 11
Oncobiologics, Inc.: Raise no. 3, Dec 2015 × Investors in this round 11 investors had bought by the notice of Dec 23, 2015: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $50 M offered; $44 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Lawrence C. Kenyon · Executive Officer Pankaj Mohan · Executive Officer, Director Albert D. Dyrness · Director Donald J. Griffith · Director Kurt J. Hilzinger · Director Robin C. Hoke · Director Scott J. Canute · Director Todd C. Brady · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Jefferies LLC (CRD 2347) · New York, New York Sold in all US states Cova Capital Partners LLC (CRD 109761) · Glen Head, New York Sold in all US states Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 23, 2015. Read the notice at the SEC .
equity SEC Sep 2015 $14 M No. 2 $10 to $50 million 4
Oncobiologics, Inc.: Raise no. 2, Sep 2015 × Investors in this round 4 investors had bought by the notice of Oct 13, 2015: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,348,686
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in New Jersey People named in the notice Lawrence Kenyon · Executive Officer Pankaj Mohan · Executive Officer, Director Donald Griffith · Director Scott Canute · Director Todd Brady · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Jefferies LLC (CRD 2347) · New York, New York Sold in all US states Citi Group Global Markets, Inc. (CRD 7059) · New York, New York Sold in all US states Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 13, 2015. Read the notice at the SEC .
equity SEC Jun 2015 $31 M No. 1 $10 to $50 million 7
Oncobiologics, Inc.: Raise no. 1, Jun 2015 × Investors in this round 7 investors had bought by the notice of Aug 10, 2015: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $31 M of $31 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,200,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in New Jersey People named in the notice Donald Griffith · Executive Officer, Director Pankaj Mohan · Executive Officer, Director Scott Canute · Director Todd Brady · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Citi Group Global Markets, Inc. (CRD 7059) · New York, New York Sold in all US states Jefferies LLC (CRD 2347) · New York, New York Sold in all US states Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 10, 2015. Read the notice at the SEC .
equity SEC